{"id":13119,"date":"2026-10-14T10:13:29","date_gmt":"2026-10-14T02:13:29","guid":{"rendered":"https:\/\/www.manhattansez.com\/?p=13119"},"modified":"2026-10-14T10:51:52","modified_gmt":"2026-10-14T02:51:52","slug":"cambodia-medical-supplies-manufacturing","status":"publish","type":"post","link":"https:\/\/www.manhattansez.com\/en\/cambodia-medical-supplies-manufacturing\/","title":{"rendered":"Is Cambodia Viable for Medical Supplies Manufacturing? Regulations, Certification and Export Routes for Gloves, Gowns, Masks and Syringes"},"content":{"rendered":"\n
\n

Summary: <\/strong>After the four-year review, US Section 301 tariffs on Chinese medical supplies rose sharply: medical gloves went to 50% in 2025 and 100% from January 2026, syringes and needles have been at 100% since September 2024, and certain masks and respirators rose to 50% in 2026. China still supplied 39% of US medical glove imports in 2024, and that capacity is now looking for new production sites.

Cambodia is one option, but medical supplies are not only a tariff question. Under Prakas 3591, medical device manufacturing requires an Initial Environmental Impact Assessment (IEIA), while medical clothing and masks made from fabric or nonwovens need only an Environmental Protection Agreement (EPA). Exports to the US require FDA establishment registration, a 510(k) for most products and compliance with the Quality Management System Regulation, which took effect in February 2026 and incorporates ISO 13485. The Section 232 investigation into medical protective equipment that the US launched in September 2025 has not concluded; if it ends with tariffs applied broadly to all sources, the tariff advantage of moving production will narrow. This article compares the four product types and sets out the permit, certification and origin points that matter for Cambodia medical supplies manufacturing.<\/p>\n<\/blockquote>\n\n\n\n

<\/p>\n\n\n\n

1. With US Tariffs on Chinese Medical Gloves at 100%, Is the Tariff Alone Enough Reason to Move Medical Supplies to Cambodia?<\/strong><\/h2>\n\n\n\n

<\/p>\n\n\n\n

No. Section 301 tariffs on Chinese medical gloves (additional duties the US imposes under Section 301 of the Trade Act on specific countries\u2019 trade practices) have been 100% since January 2026, so moving production does change the tariff bill. But whether medical supplies can be sold depends first on certification and the quality system, and certification and validation often take no less time than building the factory.<\/strong><\/p>\n\n\n\n

<\/p>\n\n\n\n

Suppose a Chinese nitrile glove maker\u2019s US customer asks for capacity outside China within 2026, and the company plans a new dipping line in Southeast Asia. The building and equipment can be ready within a year. But the new plant must complete establishment registration and device listing with the US again, the quality system has to be rebuilt at the new site and stand up to inspection, and if materials or processes change with the move, the company must assess whether a new 510(k) (the FDA\u2019s premarket notification) is needed. If this work starts only when the equipment arrives, the plant may be unable to ship for some time after production begins.<\/p>\n\n\n\n

<\/p>\n\n\n\n

The market structure shows the scale of this demand. According to comments submitted in October 2025 to the Section 232 investigation by the Coalition for a Prosperous America (CPA), a US industry group, Malaysia supplied 44% of US medical glove imports in 2024 and China 39%, while US domestic output covers less than 1% of nitrile glove demand. Prices compiled in the same submission show the average unit price of imported gloves falling from US$0.035 per glove in 2022 to US$0.028 in 2025; Chinese and Vietnamese gloves were imported at about US$0.017 to 0.018, and US-made gloves cost about US$0.061. With price competition this intense, tariff gaps directly decide where orders go.<\/p>\n\n\n\n

<\/p>\n\n\n\n

\"Cambodia<\/figure>\n\n\n\n

<\/p>\n\n\n\n

Figure 1: Sources of US medical glove imports in 2024 (compiled from CPA\u2019s October 2025 Section 232 submission).<\/em><\/p>\n\n\n\n

<\/p>\n\n\n\n

This article complements two existing pieces: Cambodia Certificate of Origin and Local Content Practice<\/a> covers general practice for proving origin, and the US Tariff Observatory for Cambodia<\/a> is the single reference for US tariffs on Cambodia. This article deals only with production conditions, permits, certification and export routes for medical supplies as a product category.<\/p>\n\n\n\n

<\/p>\n\n\n\n

2. Which Section 301 Tariffs Apply to Chinese Medical Supplies? Rates and Timeline for Gloves, Masks and Syringes<\/strong><\/h2>\n\n\n\n

<\/p>\n\n\n\n

On 13 September 2024 the Office of the US Trade Representative (USTR) published the final changes from its four-year review of the Section 301 tariffs: 100% on Chinese syringes and needles from 27 September 2024; 50% on medical gloves from 2025 and 100% from 2026; and 25% on certain textile face masks and respirators from 2024, rising to 50% in 2026.<\/strong><\/p>\n\n\n\n

<\/p>\n\n\n\n

\"US<\/figure>\n\n\n\n

<\/p>\n\n\n\n

Figure 2: Timeline of Section 301 tariff increases on Chinese medical supplies (compiled from the USTR final determination of September 2024).<\/em><\/p>\n\n\n\n

<\/p>\n\n\n\n

The review also brought disposable face masks into the scope of the mask tariff line. From 24 July 2026, the US additionally imposed country-specific duties on China and other economies under a Section 301 investigation into forced labor, stacked on top of the existing Section 301 measures on China, so the total duty on Chinese medical supplies is higher still.<\/p>\n\n\n\n

<\/p>\n\n\n\n

Products made in Cambodia are not subject to the Section 301 measures on China; they face the US country-specific additional rate for Cambodia, and the current rate and stacking rules are as published in the US Tariff Observatory for Cambodia<\/a>. The gap between the two runs from tens of percentage points to nearly 100, which is the direct reason medical supplies capacity is considering leaving China. Whether that gap can actually be captured depends on the conditions in Sections 3 to 7.<\/p>\n\n\n\n

<\/p>\n\n\n\n

3. Which Medical Supplies Suit Production in Cambodia? Conditions for Gloves, Gowns, Masks and Syringes<\/strong><\/h2>\n\n\n\n

<\/p>\n\n\n\n

The four common types of medical supplies face very different conditions in Cambodia. Protective clothing and surgical gowns involve sewing work close to the garment industry and have the lowest barrier; medical gloves depend on power supply and wastewater treatment; masks depend on imported materials; and syringes and needles require cleanrooms and sterilization capability, the highest barrier of all.<\/strong><\/p>\n\n\n\n

<\/p>\n\n\n\n

Product<\/strong><\/td>Main materials<\/strong><\/td>Key processes and resources<\/strong><\/td>Key conditions in Cambodia<\/strong><\/td><\/tr><\/thead>
Medical gloves (nitrile, latex)<\/td>Nitrile latex must be imported; natural latex is available locally<\/td>Dipping lines run continuously, use much power and water and generate industrial wastewater<\/td>Stable power supply and wastewater treatment capacity<\/td><\/tr>
Protective clothing and surgical gowns<\/td>Nonwovens and laminated films are mostly imported<\/td>Cutting, sewing, heat-sealed seam taping<\/td>Sewing skills close to the garment industry, so labor transfers more easily<\/td><\/tr>
Medical masks<\/td>Meltblown and nonwoven fabrics are mostly imported<\/td>Automated forming; some products require sterilization<\/td>Material supply and outsourced sterilization arrangements<\/td><\/tr>
Syringes and needles<\/td>Medical-grade plastic resin, needle tube steel<\/td>Precision injection molding, cleanrooms, ethylene oxide sterilization and validation<\/td>Cleanroom and sterilization capability; the highest barrier<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

<\/p>\n\n\n\n

Table 1: Conditions for producing four types of medical supplies in Cambodia (compiled from product processes and public information).<\/em><\/p>\n\n\n\n

<\/p>\n\n\n\n

Gloves need a separate note on materials. Cambodia produces natural rubber: according to the General Directorate of Rubber, it produced about 307,000 tonnes and exported about 257,000 tonnes in the first ten months of 2025, a raw material that latex gloves can source locally. The US medical glove market, however, is dominated by nitrile gloves, and nitrile latex is a synthetic material that must be sourced from outside, so the material advantage applies only to some product lines.<\/p>\n\n\n\n

<\/p>\n\n\n\n

4. Which Permits Are Needed to Make Medical Supplies in Cambodia? EIA Classes and Ministry of Health Registration<\/strong><\/h2>\n\n\n\n

<\/p>\n\n\n\n

The EIA class for making medical supplies in Cambodia depends on the product. Under Prakas 3591, medical device manufacturing requires an Initial Environmental Impact Assessment (IEIA), while medical clothing, masks and bandages made from fabric or nonwovens need only an Environmental Protection Agreement (EPA). Products to be sold in Cambodia must also be registered with the Ministry of Health\u2019s Department of Drugs and Food.<\/strong><\/p>\n\n\n\n

<\/p>\n\n\n\n

Annex item<\/strong><\/td>Project type (translated from the Khmer original)<\/strong><\/td>EIA class<\/strong><\/td><\/tr><\/thead>
Item 168<\/td>Factories manufacturing medical machinery and devices of all kinds<\/td>IEIA (any size)<\/td><\/tr>
Item 169<\/td>Pharmaceutical manufacturing factories<\/td>IEIA (any size)<\/td><\/tr>
Item 171<\/td>Factories assembling medical machinery and devices of all kinds<\/td>EPA (any size)<\/td><\/tr>
Item 172<\/td>Factories making medical articles from fabric or nonwovens (clothing, masks, caps, bandages, cotton, etc.)<\/td>EPA (any size)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

<\/p>\n\n\n\n

Table 2: EIA classes for medical supplies manufacturing in the \u201chealth sector\u201d section of the Prakas 3591 annex (compiled from the annex issued by Cambodia\u2019s Ministry of Environment on 6 May 2025).<\/em><\/p>\n\n\n\n

<\/p>\n\n\n\n

The table has a direct bearing on product choice. Protective clothing, surgical gowns and masks fall under Item 172 and go through the EPA route with a 30-working-day review. Dipped gloves and injection-molded syringes are not fabric products and are more likely to be classified under Item 168 as IEIA, with a 60-working-day review. The actual class is determined by the Ministry of Environment and is best confirmed at the evaluation stage.<\/p>\n\n\n\n

<\/p>\n\n\n\n

Sales authorization is a separate track. Medical devices in Cambodia are regulated by the Ministry of Health\u2019s Department of Drugs and Food (DDF), which registers them in four risk classes, A to D, under Prakas No. 1258 of 8 November 2012. According to local regulatory consultants, registration must be filed by a licensed local importer that employs a Cambodian pharmacist. For export-oriented projects that do not sell in Cambodia, market access is decided by the importing country\u2019s certification, covered in the next section.<\/p>\n\n\n\n

<\/p>\n\n\n\n

5. Which Certifications Do Medical Supplies Made in Cambodia Need for the US and EU? FDA Registration, 510(k), QMSR and CE Marking<\/strong><\/h2>\n\n\n\n

<\/p>\n\n\n\n

Medical supplies exported to the US require establishment registration and device listing with the US Food and Drug Administration (FDA), a 510(k) premarket notification for most products, and compliance with the Quality Management System Regulation (QMSR), which took effect on 2 February 2026 and incorporates ISO 13485 by reference. Exports to the EU require CE marking under the Medical Device Regulation (MDR).<\/strong><\/p>\n\n\n\n

<\/p>\n\n\n\n

Market<\/strong><\/td>Requirement<\/strong><\/td>Key points<\/strong><\/td><\/tr><\/thead>
US<\/td>Establishment registration and device listing<\/td>Renewed annually; foreign establishments must designate a US agent<\/td><\/tr>
US<\/td>510(k) premarket notification<\/td>Examination gloves are Class I but still require a 510(k); surgical masks and syringes are Class II<\/td><\/tr>
US<\/td>Quality Management System Regulation (QMSR)<\/td>Replaced the previous rule from 2 February 2026, incorporating ISO 13485:2016<\/td><\/tr>
EU<\/td>CE marking under the Medical Device Regulation (MDR)<\/td>Depending on risk class, some products require notified body review<\/td><\/tr>
Cambodia<\/td>Department of Drugs and Food registration<\/td>Required only for sales in Cambodia; Classes A to D<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

<\/p>\n\n\n\n

Table 3: Main market-access requirements for exporting medical supplies to the US and EU and for selling in Cambodia (compiled from public information from the FDA, the EU and Cambodia\u2019s Ministry of Health).<\/em><\/p>\n\n\n\n

<\/p>\n\n\n\n

QMSR is the most important change in 2026. The FDA published the final rule in January 2024, amending 21 CFR Part 820 to incorporate ISO 13485:2016 by reference, effective 2 February 2026. For a new factory, one quality system can now serve both FDA inspection and ISO 13485 certification, without maintaining two sets of documents.<\/p>\n\n\n\n

<\/p>\n\n\n\n

The key to certification lies in the words \u201cnew factory\u201d. Establishment registration and device listing are tied to the production site, so a company moving capacity from China to Cambodia must register the new plant afresh and make sure its quality system can withstand inspection. A 510(k) applies to the product itself; if the move also changes materials, processes or specifications, the company must assess whether to resubmit under the FDA\u2019s guidance on changes to existing devices. The safer approach is to run certification in parallel with construction: plan the validation protocol when selecting equipment, and use trial production batches as certification samples.<\/p>\n\n\n\n

<\/p>\n\n\n\n

6. Where Do Medical Supplies Made in Cambodia Originate? Substantial Transformation and Evidence<\/strong><\/h2>\n\n\n\n

<\/p>\n\n\n\n

The US determines origin by \u201csubstantial transformation\u201d: goods count as Cambodian only if they acquire a new name, character and use in Cambodia. Medical gloves dip-formed in Cambodia can satisfy this principle relatively easily; if Chinese-made parts or semi-finished products are merely assembled or packed in Cambodia, they risk being treated as Chinese-origin.<\/strong><\/p>\n\n\n\n

<\/p>\n\n\n\n

Take syringes. If the barrel, plunger and needle are all molded or formed in China and Cambodia only assembles and packs them, whether that step amounts to substantial transformation is for US Customs to decide; carrying out molding, assembly and sterilization in one place makes the origin case much stronger. Protective clothing and surgical gowns are similar to garments: cutting and sewing in Cambodia are usually the decisive operations.<\/p>\n\n\n\n

<\/p>\n\n\n\n

7. What Could Change the Numbers? The Section 232 Investigation, Certification Lead Times and Origin Rules<\/strong><\/h2>\n\n\n\n

<\/p>\n\n\n\n

The biggest variable is the Section 232 investigation into personal protective equipment, medical consumables and medical equipment that the US launched on 2 September 2025. Its scope covers gloves, masks, surgical gowns, syringes and needles, and as of September 2026 no result had been published. If it ends with tariffs applied broadly to all sources, the tariff advantage of moving production will shrink sharply.<\/strong><\/p>\n\n\n\n

<\/p>\n\n\n\n

Section 232 measures differ in nature from Section 301: the former are justified on national security grounds and usually apply broadly to all sources, as with the measures on steel, aluminum, copper and automobiles; the latter target specific countries. If medical supplies are brought under Section 232 measures, the duty gap between Cambodian and Chinese products may narrow, and the main reasons to move production will revert to supply chain diversification and customer requirements rather than tariffs. Pharmaceuticals already offer a precedent: on 2 April 2026 the US announced 100% Section 232 tariffs on patented drugs and active pharmaceutical ingredients from 31 July, while Japan, the EU, South Korea, Switzerland and others that had reached agreements with the US face 15%. Section 232 measures therefore do not necessarily apply the same rate to every source; if medical supplies are covered in future, whether Cambodia can obtain a lower rate will also depend on bilateral negotiations.<\/p>\n\n\n\n

<\/p>\n\n\n\n

Another point to watch is that origin rules may tighten. In the same submission, CPA recommended that origin determinations for medical supplies go beyond the traditional substantial transformation standard and also consider the source of materials and corporate control. This is only an industry group\u2019s recommendation, not regulation, but it suggests that origin determinations for Chinese-owned factories in third countries may face closer scrutiny in future.<\/p>\n\n\n\n

<\/p>\n\n\n\n

Certification lead time is the variable on the time axis. The Section 301 gap already exists, but registering the new plant, preparing 510(k) submissions and building the quality system take time; if policy has changed by the time certification is complete, the payback period of the initial investment lengthens. Not every medical product is suited to moving now: products made in small batches and many varieties, or those relying on sterile components and sterilization services supplied from China, will find it hard at this stage to form a complete production and origin chain in Cambodia and are poor candidates for the first wave.<\/p>\n\n\n\n

<\/p>\n\n\n\n

8. What Site Infrastructure Do Medical Factory Audits Examine? Power, Wastewater and Fire Safety at Manhattan SEZ<\/strong><\/h2>\n\n\n\n

<\/p>\n\n\n\n

To pass FDA inspection, notified body audits and customer audits, a medical supplies factory is judged not only on its production floor but also on site-level infrastructure: whether power is continuous, whether wastewater is discharged in compliance, and whether fire protection and safety are complete. Much of this is provided by the special economic zone.<\/strong><\/p>\n\n\n\n

<\/p>\n\n\n\n

When selecting a site, start with four questions from the audit checklist. Is the power supply dual-circuit, and what keeps the line running during an outage? Where does industrial wastewater go, and does the treatment plant hold a license and provide the online monitoring and discharge records that audits require? Does the zone have a full-time fire brigade and fire engines? Where are import, export and origin documents handled? The answers to all four will later appear in audit reports and in the site records of certification audits.<\/p>\n\n\n\n

<\/p>\n\n\n\n

Manhattan SEZ is located in Bavet, Svay Rieng Province. It is the only special economic zone in Cambodia with a dual-circuit high-voltage power supply, with 80 MW of capacity and a dedicated 115 kV substation. It was the first special economic zone in Cambodia to obtain a wastewater license; its treatment plant handles 5,000 cubic meters a day with 24\/7 online monitoring, and water supply is 5,000 tonnes a day. It was also the first zone equipped with professional fire facilities, with a 15-member fire brigade and 2 fire engines on duty around the clock. A government one-stop service center in the zone hosts the Ministry of Commerce and customs, so import and export formalities and certificates of origin can be handled on site. The zone is about 6 km from the Cambodia\u2013Vietnam border and about 90 km from the Ho Chi Minh City port area, so imported nitrile latex, nonwovens and packaging can reach the factory through the land border crossing.<\/p>\n\n\n\n

<\/p>\n\n\n\n

These are site-level conditions; FDA registration, 510(k), the quality system and CE certification for the products must still be obtained by the company under each market\u2019s regulations. If your company is evaluating where to locate medical supplies capacity, please use the Manhattan SEZ advisory team contact form<\/a> to share your product categories and target markets, planned production lines with their power and water needs, and whether sterilization is involved. The zone will then explain its power and wastewater conditions, the site documents it can provide, and what it can help coordinate during the EIA application.<\/p>\n\n\n\n

<\/p>\n\n\n\n

9. Cambodia Medical Supplies FAQ: Tariffs, EIA, Registration and Certification<\/strong><\/h2>\n\n\n\n

<\/p>\n\n\n\n

Q1: What is the current US tariff on Chinese medical gloves?<\/strong><\/p>\n\n\n\n

<\/p>\n\n\n\n

The Section 301 portion is 100%, applicable from 1 January 2026; it was 50% in 2025. In addition, the Section 301 forced-labor measure imposed on China from July 2026 is stacked on top, and both apply in addition to the most-favored-nation rate.<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

<\/p>\n\n\n\n

Q2: Does making medical supplies in Cambodia require an EIA?<\/strong><\/p>\n\n\n\n

<\/p>\n\n\n\n

Yes, and the class depends on the product. Under Prakas 3591, medical clothing, masks and similar articles made from fabric or nonwovens need only an Environmental Protection Agreement, with a 30-working-day review; medical device manufacturing is classed as an Initial Environmental Impact Assessment, with a 60-working-day review.<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

<\/p>\n\n\n\n

Q3: Which authority registers medical devices in Cambodia?<\/strong><\/p>\n\n\n\n

<\/p>\n\n\n\n

The Ministry of Health\u2019s Department of Drugs and Food (DDF). Under Prakas No. 1258 of 2012, medical devices are registered in four risk classes, A to D, and filings must be made by a licensed local importer that employs a Cambodian pharmacist; for products that are exported and not sold in Cambodia, the importing country\u2019s certification is what matters.<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

<\/p>\n\n\n\n

Q4: Which certifications do medical gloves made in Cambodia need for the US market?<\/strong><\/p>\n\n\n\n

<\/p>\n\n\n\n

FDA establishment registration and device listing, a 510(k) premarket notification, and compliance with the QMSR quality system rule, which has incorporated ISO 13485 since February 2026. Establishment registration is tied to the production site, so a plant moved from China must be registered as a new establishment; the 510(k) applies to the product, and changes in materials or processes require an assessment of whether to resubmit.<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

<\/p>\n\n\n\n

Q5: Will the US Section 232 investigation into medical supplies affect factories in Cambodia?<\/strong><\/p>\n\n\n\n

<\/p>\n\n\n\n

It may. The investigation began in September 2025 and covers gloves, masks, surgical gowns and syringes; as of September 2026 there was no result. Section 232 measures usually apply broadly to all sources, although economies with separate agreements with the US may face lower rates. If tariffs are raised on this basis, the tariff gap between Cambodian and Chinese products would narrow.<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

<\/p>\n\n\n\n

10. Sources and References<\/strong><\/h2>\n\n\n\n

<\/p>\n\n\n\n

\ud83d\udcda References<\/strong><\/p>\n\n\n\n

<\/p>\n\n\n\n